Selective Screening for Metabolic Disorders in the Slovenian Pediatric Population

Barbka Repič Lampret1, Simona Murko1, Mojca Žerjav Tanšek2

  • 1Unit for Special Laboratory Diagnostics, University Children's Hospital, University Medical Centre Ljubljana, Slovenia.

Insights

Selective screening aids in diagnosing inborn errors of metabolism (IEM), rare genetic disorders impacting child health. Slovenia

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Inborn errors of metabolism (IEM) are rare genetic disorders caused by enzyme defects, leading to significant childhood morbidity and mortality.
  • Early diagnosis of IEM is crucial for preventing severe complications and improving patient outcomes.
  • Selective screening plays a vital role in the timely diagnosis of IEM.

Purpose of the Study:

  • To outline the diagnostic approaches and current patient registry for inborn errors of metabolism in Slovenia.
  • To assess the current status of IEM diagnosis and management within the Slovenian healthcare system.

Main Methods:

  • Symptomatic patients with suspected IEM are referred to the University Children's Hospital Ljubljana for diagnosis.
  • Diagnostic techniques include gas chromatography-mass spectrometry, ion exchange chromatography-post-column derivatization, liquid chromatography-tandem mass spectrometry, isoelectric focusing, and fluorimetric enzyme activity measurement.
  • Data on diagnosed IEM cases are maintained in the Slovenian Register for Rare Diseases.

Main Results:

  • The Slovenian Register for Rare Diseases includes 168 patients with amino and organic acidemias, 5 with fatty acid metabolism disorders, 1 with congenital glycosylation disorder, 42 with Fabry disease, and 20 with Gaucher disease.
  • A significant number of adult patients with Fabry and Gaucher disease are noted in the registry.

Conclusions:

  • Patient management for IEM in Slovenia is centralized at the University Children's Hospital, with specific exceptions for adult Fabry and Gaucher disease patients.
  • Organized teamwork and close collaboration between laboratories and pediatricians specialized in metabolic disorders characterize the management approach.
  • The study anticipates a potential need for expanded newborn screening, as current results are lower than expected based on literature frequencies, prompting plans for a pilot study.
Abstract

Related Concept Videos

Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...